Xeris Biopharma Holdings, Inc. XERS
9.10
0.15
1.68%
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow XERS
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 2,065.79 | 78.59 | 0.00 |
P/S ratio |
5.01 | 4.32 | 3.14 | 4.08 | |
P/FCF ratio |
133.55 | 45.09 | 20.81 | 24.59 | |
P/Operating CF |
72.27 | 62.83 | 100.21 | 165.65 | |
P/B ratio |
0.00 | 92.00 | 76.02 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.53 | 4.73 | 3.53 | 4.47 | |
EV/EBITDA |
57.14 | 33.70 | 21.32 | 28.35 | |
EV/Operating CF |
139.41 | 48.23 | 22.88 | 26.49 | |
EV/FCF |
147.56 | 49.43 | 23.37 | 26.94 | |
Quick Ratio |
1.25 | 1.48 | 1.42 | 0.95 | |
Current Ratio |
1.93 | 2.19 | 2.12 | 1.45 | |
Net Debt/EBITDA |
11.88 | 5.25 | 9.11 | 14.08 | |
Debt/Assets |
59.29% | 57.45% | 56.43% | 61.32% | |
Debt/Equity |
(254.90) | 16.10 | 17.00 | (25.95) | |
Asset Turnover |
0.77 | 0.83 | 0.89 | 0.90 | |
Operating CF/Net income |
29.68 | 1.81 | 4.42 | (0.27) | |
Capex/Depreciation |
(0.02) | (0.08) | (0.08) | (0.05) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.06% | 9.18% | 10.57% | 11.58% | |
Selling, General and Administrative Expense of Revenue |
62.46% | 55.36% | 63.93% | 66.27% | |
Intangible Assets out of Total Assets |
0.31 | 0.29 | 0.28 | 0.26 | |
Share Based Compensation of Revenue |
10.28% | 6.14% | 4.98% | 12.02% | |
Graham Net Nets |
(0.11) | (0.10) | (0.13) | (0.11) | |
Graham Number |
0.11 | 0.09 | 0.36 | 0.35 | |
Earnings Yield |
(1.18%) | 0.05% | 1.27% | (1.21%) | |
Free Cash Flow Yield |
0.75% | 2.22% | 4.80% | 4.07% | |
Revenue per Share |
0.45 | 0.53 | 0.49 | 0.53 | |
Operating CF per Share |
0.11 | 0.12 | 0.06 | 0.05 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.11 | 0.12 | 0.06 | 0.05 | |
Cash per Share |
0.56 | 0.69 | 0.66 | 0.70 | |
Shareholders Equity per Share |
(0.01) | 0.09 | 0.08 | (0.06) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.01) | 0.09 | 0.08 | (0.06) | |
Free Cash Flow |
18.36 | 19.71 | 9.55 | 8.05 | |
Working Capital |
107.82 | 130.74 | 133.09 | 85.19 | |
Capital Expenditures |
(0.07) | (0.33) | (0.32) | (0.21) | |
Net Current Asset Value |
(147.03) | (129.52) | (127.32) | (146.88) | |
EV/EBIT |
150.17 | 55.45 | 30.93 | 40.98 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.83% | 12.91% | 2.69% | (33.77%) | |
Price to Operating Income |
135.90 | 50.58 | 27.55 | 37.40 | |
| Other line items | |||||
Average Receivables |
47.44 | 45.73 | 51.31 | 55.58 | |
Average Payables |
6.99 | 2.68 | 8.91 | 9.40 | |
Average Inventory |
56.29 | 58.42 | 63.46 | 74.11 | |
Average Assets |
345.65 | 353.29 | 353.73 | 373.30 | |
Average Common Equity |
(14.59) | (7.96) | (11.06) | (14.52) |
Columns are period end dates